Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07612605
EARLY_PHASE1

Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia

Sponsor: Chinese PLA General Hospital

View on ClinicalTrials.gov

Summary

Through a prospective randomized controlled trial, we systematically evaluate the effects of Yiqi Huoxue Jiedu Formula combined with bacteriophage therapy on the bacterial clearance rate, disease improvement rate and mortality rate in patients with severe pneumonia caused by drug-resistant bacteria, so as to clarify its clinical transformation value.

Official title: A Randomized Controlled Trial (RCT) of Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia Caused by Drug-resistant Gram-negative Bacilli

Key Details

Gender

All

Age Range

18 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

250

Start Date

2026-06-01

Completion Date

2029-12-31

Last Updated

2026-05-29

Healthy Volunteers

No

Conditions

Interventions

DRUG

YHDF placebo

7-14 days treatment with YHDF placebo

DRUG

Bacteriophage Placebo

7-14 days treatment with bacteriophage placebo

DRUG

YHDF Drug

7-14 days treatment with YHDF

DRUG

Bacteriophage

7-14 days treatment with bacteriophage

Locations (4)

The First Affiliated Hospital of Guangzhou Medical University

Guangdong, Guangzhou, China

The First Affiliated Hospital of Guangzhou University of Chinese Medicine

Guangdong, Guangzhou, China

1st Medical Center of Chinese PLA General Hospital

Beijing, China

8th Medical Center of Chinese PLA General Hospital

Beijing, China